Chi-Med and BeiGene start clinical cooperation

Hutchison China MediTech Limited (Chi-Med) today announced a clinical development cooperation agreement with BeiGene.

Hutchison China MediTech Limited (Chi-Med) today announced a clinical development cooperation agreement with BeiGene.

The two parties will carry out clinical trials in the United States, Europe, China and Australia to evaluate the safety, tolerability and efficacy of combined treatment of various solid tumors, of Chi-Med’s the candidate drugs sofatinib and fruquintinib, and BeiGene ’s anti-programmed death receptor 1 (PD-1 ) antibody Tislelizumab.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/27/chi-med-and-beigene-start-clinical-cooperation/.

Leave a Reply

Your email address will not be published. Required fields are marked *